Quick Answer
Lyell Immunopharma, Inc. reported Earnings Per Share Diluted of $16.06 (loss) per share for the year ending 2025.
- Lyell Immunopharma, Inc. showed an increase of +38.8% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Lyell Immunopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $3.19 (loss) per share | Q2 2021: $1.47 (loss) per share | Q3 2021: $0.20 (loss) per share | Q1 2022: $0.28 (loss) per share | Q2 2022: $0.15 (loss) per share | Q3 2022: $0.28 (loss) per share | Q1 2023: $0.27 (loss) per share | Q2 2023: $0.26 (loss) per share | Q3 2023: $0.20 (loss) per share | Q1 2024: $0.24 (loss) per share | Q2 2024: $3.59 (loss) per share | Q3 2024: $3.48 (loss) per share | Q1 2025: $0.18 (loss) per share | Q2 2025: $2.89 (loss) per share | Q3 2025: $2.13 (loss) per share.
- Over the full 7 years of available data (2019 to 2025), Lyell Immunopharma, Inc.'s Earnings Per Share Diluted has grown by 33.2%.
- Historical annual values: Fiscal year 2025: $16.06 (loss) per share | Fiscal year 2024: $26.23 (loss) per share | Fiscal year 2023: $18.70 (loss) per share | Fiscal year 2022: $0.74 (loss) per share | Fiscal year 2021: $1.84 (loss) per share | Fiscal year 2020: $15.69 (loss) per share | Fiscal year 2019: $24.04 (loss) per share.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: